tiprankstipranks
Alkermes (DE:8AK)
BERLIN:8AK
TipRanksstock market overviewAlkermes Stock Analysis & Ratings

Alkermes Stock Analysis & Ratings

0 Followers

8AK Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€24.4
Volume0.00
Average Volume (3M)950.00
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta-0.07
Next EarningsOct 26, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)N/A
Shares Outstanding164,136,728
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume28
30 Day Avg. Volume950
P/B Ratio5.26
P/S Ratio5.13
P/CF Ratio28.20
P/FCF Ratio45.20
Total Debt€385.60M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside23.01% Upside
Rating ConsensusHold
AlphaN/A
Number of Analyst Covering5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

8AK FAQ

What was Alkermes’s price range in the past 12 months?
Currently, no data Available
What is Alkermes’s market cap?
Currently, no data Available
What is Alkermes’s price target?
The average price target for Alkermes is €30.01. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is €33.13 ,the lowest forecast is €26.31. The average price target represents 23.01% Increase from the current price of €24.395.
    What do analysts say about Alkermes?
    Alkermes’s analyst rating consensus is a ‘Hold. This is based on the ratings of 5 Wall Streets Analysts.
      When is Alkermes’s upcoming earnings report date?
      Alkermes’s upcoming earnings report date is Oct 26, 2022 which is in 73 days.
        How were Alkermes’s earnings last quarter?
        Alkermes released its earnings results on Jul 27, 2022. The company reported €0.058 earnings per share for the quarter, beating the consensus estimate of €0.007 by €0.052.
          Is Alkermes overvalued?
          According to Wall Street analysts Alkermes’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Alkermes pay dividends?
            Alkermes does not currently pay dividends.
            What is Alkermes’s EPS estimate?
            Alkermes’s EPS estimate is €0.03.
              How many shares outstanding does Alkermes have?
              Currently, no data Available
              What happened to Alkermes’s price movement after its last earnings report?
              Alkermes reported an EPS of €0.058 in its last earnings report, beating expectations of €0.007. Following the earnings report the stock price went up 1.123%.
                Which hedge fund is a major shareholder of Alkermes?
                Among the largest hedge funds holding Alkermes’s share is PRIMECAP Management Co. It holds Alkermes’s shares valued at 149M.

                  ---

                  Alkermes Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  6

                  Analyst Forecast

                  Hold
                  Average Price Target: €30.01

                  Blogger Sentiment

                  Bullish
                  DE:8AK Sentiment 100% Sector Average 69%

                  Insider Transactions

                  N/A
                  Currently Not Enough Data Available

                  News Sentiment

                  Positive
                  Bullish 100% Bearish 0%

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  -9.70%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -8.64%
                  Trailing 12-Months
                  Asset Growth
                  1.02%
                  Trailing 12-Months
                  The Alkermes Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Alkermes

                  Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Horizon Therapeutics
                  Prothena
                  Amarin
                  Acorda Therapeutics
                  Johnson & Johnson

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis